Adi Renbaum joined the Neocure Group shortly after it was founded in 2006, and today heads its Washington DC office, where she manages a portfolio of clients and ensures Neocure’s expertise and network of experts are available to meet client needs.  Ms. Renbaum leads the Health Policy and Reimbursement practice, in which she oversee engagements to develop robust market access strategies that leverage the newest health policy strategies, to meet clients’ business objectives: optimize provider adoption, patient access, and payment for novel medical devices and biotechnology therapies. 

Ms. Renbaum has more than 17 years’ experience addressing payer demands, opportunities, and barriers, and bringing to bear FDA regulatory and clinical development strategies to support commercialization of products ranging from office-based diagnostics and procedures to hospital-based, complex surgical procedures.  She has negotiated directly with CMS and commercial payers to expand coverage and secure reimbursement for clients’ technologies; and works closely with medical and specialty societies to build consensus about innovative products and for support with payers.

Prior to joining Neocure, Ms. Renbaum served as Vice President of Strategic Planning and Services at EyeTel Imaging from 2004.  In that role, she led efforts to improve the standard of care of diabetic eye exams to annual, primary-care based retinal imaging and disease monitoring by securing universal coverage among commercial health plans (Aetna, CIGNA, Humana, United HealthCare, BCBS Association and regional plans).  Ms. Renbaum established local Medicare coverage decisions to allow payment for detection of diabetic retinopathy; managed advocacy that led to the American Diabetes Association (ADA) 2006 Clinical Recommendations that support retinal imaging in primary care; and fostered advocacy initiatives within the American Academy of Family Physicians; American Association of Clinical Endocrinology; National Commission for Quality Assurance; and Regional ADA organizations.

Ms. Renbaum has chaired numerous advisory boards of national physician thought leaders and manufacturers on treatment and payment for diabetes care.  Prior to EyeTel, Ms. Renbaum consulted for medical products and pharmaceutical companies and provided strategic advice that included innovative payer adoption strategies, initiation of new CPT codes, and definition of market opportunities in multiple payer-driven markets.

Prior experiences include Director of Payer Relations at Inoveon Corporation until 2003.  There, Ms. Renbaum championed national coverage policy decisions with leading health plans, and built and managed a field-based team that interacted directly with payers.  She served on the senior management teams of both Inoveon and The Women’s Care Network, in the capacity of Director of Business Development.

Ms. Renbaum started her career at Covance Health Economics and Outcomes Services (now Market Access Services).  Her clients included pharmaceutical, biotechnology, and medical device companies, and she led projects such as reimbursement assessments, financial models for sales/field force, reimbursement support programs (help lines, assistance programs), policy research and reporting, and direct payer intervention.

Ms. Renbaum holds an M.B.A. from the Fuqua School of Business, Duke University, and graduated cum laude from George Washington University with a B.B.A. in Marketing Management.